Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Myometrial involvement by cancer metastasis after pathology examination

Absence of myometrial involvement by cancer metastasis after pathology examination

Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery

Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.

Investigators studied a population of 28 low grade serous ovarian carcinoma treated in Hospices civils de Lyon between 2000 and 2022. The primary objective is to determinate the rate of myometrial involvement by the cancer at pathology examination. Then, investigators compared patients with or without myometrial involvement : survival parameters, predictive factors of myometrial involvement (age, CA 125 level, surgery characteristics, pathology characteristics).

Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule

LOw Grade Serous Ovarian Carcinoma and Uterine Involvement : Should hYSTerectomy be the Rule

Myometrial involvement after pathology examination

Hospices Civils de Lyon

Cystadenocarcinoma, Serous

Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.

Diane C. Bodurka, MD, BS

Primary Objective:

* To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system.

Secondary Objective:

* To determine the overall and progression-free survival of patients with serous carcinoma of the ovary treated on GOG protocol 158 when reclassified according to tumor grade (low vs. high).

Tertiary Objective:

* To correlate histologic grade with other prognostic factors.

The purpose of this study is to describe the progression-free and overall survival of patients treated on GOG protocol 158 when their tumors are reclassified into a two-tier grading system. Although no universal grading system exists, Malpica et al. have recently published data on a clinically meaningful two-tier grading system for serous ovarian carcinoma (Malpica et al., American Journal of Surgical Pathology, 2004). Tumor grade has been shown to be an important prognostic factor in women with epithelial ovarian cancer, especially in early stage carcinomas. While there is less consensus regarding the prognostic significance of grade in late stage tumors, researchers have noted that patients with low-grade advanced disease may have a longer survival than those with high-grade lesions (Bodurka-Bevers et al., Gynecologic Oncology, 2000).

Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System

An Ancillary Study of Patients With Advanced Stage Serous Carcinoma of the Ovary Treated on GOG Protocol 158: A Survival Analysis Based on Reclassification to a Two-tier Grading System

Gynecologic Oncology Group

M.D. Anderson Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule	NCT05741554	Serous Ovarian ... Low Grade Serou...	Rate of myometr...	-	Hospices Civils de Lyon
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System	NCT00837993	Ovarian Cancer		-	M.D. Anderson Cancer Center
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System	NCT00837993	Ovarian Cancer		-	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for serous ovarian carcinoma